Program
INNA-051
Its studies are mostly in Influenza, Human · COVID-19, led by ENA Respiratory Pty.
Furthest: phase 2, since Oct 27, 20213 company-led studies, 1 open or runningNext primary completion: Mar 12, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ENA Respiratory Pty | 31 open or running | phase 2since Oct 27, 2021 | Oct 27, 2021 | Mar 12, 2027phase 2 · NCT07222670 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2021First study: phase 2 study in COVID-19First studyNCT05118763
- Jan 27, 2022Phase 2 study in Influenza ProphylaxisNCT05255822 · 123 enrolled · United Kingdom
- Oct 28, 2025Phase 2 study in Viral Respiratory InfectionNCT07222670 · 1,100 planned · United States
Ahead
- Mar 12, 2027Primary completion: phase 2 study in Viral Respiratory InfectionNCT07222670
TargetBeta
TLR2 →read by rule
“INNA-051, a TLR2/6 agonist, is being developed as an intranasal innate immune-boosting prophylactic approach for individuals at risk for symptoms and/or complications resulting from respiratory viral infections due to age, occupation, and/or co-morbidities.”study text, by rule · the study
Other programs on TLR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| NM-101rule | neuramedy-co-ltd | phase 1 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07222670Viral Respiratory Infection · United States | 2 | Recruiting | Mar 12, 2027 | 1,100 |
| NCT05255822Influenza Prophylaxis · United Kingdom | 2 | Completed | Aug 23, 2022 | 123 |
| NCT05118763COVID-19 | 2 | Withdrawn | Dec 31, 2022 | 0 |
How it is read
Names in the registry
- “INNA-051”, 3 entries
Conditions, from the studies’ own filings
- Influenza, Human, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.